On July 14, WuXi XDC rose 3.05% in regular trading, trading at 58.75 HKD/share, with turnover of HKD 254 million.

On the news front, multiple international investment banks recently issued bullish research reports on the company. CLSA raised its target price to 82.6 HKD while maintaining an Outperform rating, projecting revenue growth of 33%, 31%, and 28% for the next three years. Daiwa initiated coverage with a Buy rating and a 78 HKD target price, designating WuXi XDC as a top pick in China's CXO sector, citing its 24% global ADC outsourcing market share and full-chain CRDMO capabilities.

The broader Life Sciences Tools & Services sector rallied in sympathy, with Pharmaron up 6.49%, WuXi AppTec up 5.54%, and WuXi Biologics up 2.95%. On the fundamental side, the company's backlog stands at approximately USD 1.489 billion, up 50.3% year-over-year, with new contract value of USD 1.33 billion representing 41% growth, underpinning strong earnings visibility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)